GlassScriptPhysician profile
Kevin L Pulsipher
NPI 1093754491
$625.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $103 · 2022: $198 · 2024: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $85.91 | 2022 | |
| Abbvie INC. | $80.28 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $61.05 | 2019-2024 | Breztri |
| Astellas Pharma US INC | $60.63 | 2019-2024 | Veozah |
| Pfizer INC. | $52.87 | 2019-2020 | |
| Allergan, INC. | $52.41 | 2020 | |
| Grifols USA, LLC | $45.90 | 2024 | Prolastin-C Liquid |
| Amgen INC. | $40.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.52 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.34 | 2022 | |
| Lilly USA, LLC | $23.06 | 2019-2020 | |
| Pacira Therapeutics, INC. | $20.37 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.55 | 2022 | |
| Celgene Corporation | $18.45 | 2024 | Reblozyl |
| Sanofi Pasteur INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Pulsipher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.